激光联合大隐静脉高位结扎治疗下肢静脉曲张的护理

目的探讨激光联合大隐静脉高位结扎治疗下肢静脉曲张的护理措施。方法我院应用激光(EVLT)联合手术治疗下肢静脉曲张患者真10例,术前、术后给予精心护理。结果患者均一期愈合,无下肢静脉血栓等并发症发生。结论EVLT联合大隐静脉高位结扎治疗下肢静脉曲张具有安全、有效、微创、操作简便、手术疤痕小、不易复发等优点,做好手术前后的护理是保证手术成功的关键。     

高位结扎联合腔内激光术治疗大隐静脉曲张临床分析

目的评价高位结扎联合腔内激光术（EVLT）治疗大隐静脉曲张的方法及疗效。方法回顾性分析2009年6月至2011年6月柘城县人民医院普外科采用高位结扎联合EVLT治疗大隐静脉曲张69例患者98腿的临床资料,并与随机抽取的2007年6月至2009年6月采用的传统高位结扎联合剥脱手术治疗下肢大隐静脉曲张75例患者106腿作对照研究。结果高位结扎联合EVLT在手术时间、切口数量、术中失血量、术后住院时间、术后并发症、一年复发率方面均较传统手术明显减少或者缩短（P〈0．05）。结论高位结扎联合EVLT是治疗大隐静脉曲张的有效方法,与传统手术相比更具优势。     

大隐静脉高位结扎联合腔内激光闭合术治疗下肢静脉曲张疗效分析

目的探讨高位结扎联合腔内激光闭合术(EVLT)治疗大隐静脉曲张的疗效。方法对80例大隐静脉曲张患者采用连续硬膜外麻醉下先高位结扎大隐静脉及其属支后行EVLT治疗。结果 80例患者伤口均Ⅰ期愈合,无感染发生。术后随访6～12个月,无一例复发,恢复均良好,治疗效果满意。结论高位结扎联合腔内激光术是治疗大隐静脉曲张的理想方法。     

静脉腔内激光联合高位结扎治疗下肢浅静脉曲张63例分析

目的 评价应用静脉腔内激光联合高位结扎微创治疗下肢浅静脉曲张的效果.方法 对2008年4月～2009年8月我院收治的63例(82条静脉)下肢浅静脉曲张采取静脉腔内激光联合高位结扎治疗,观察临床效果.结果 手术操作顺利,患者术后均恢复良好,出院随访6～12个月,临床症状无复发,手术相关并发症痊愈.结论 静脉腔内激光联合高位结扎疗法具有微创、安全、手术操作简便、疗效可靠的优点,适用于下肢浅静脉曲张的治疗.     

内镜下交通静脉离断联合手术治疗下肢静脉性溃疡

目的内镜下交通支离断术subfascial endoscopic perforator vein surgery（SEPS）联合手术治疗下肢静脉性溃疡76例的疗效观察。方法下肢静脉性溃疡患者76例,共82条患肢。按不同病因分为3组,采用SEPS＋相应手术方法治疗：A组：中、重度原发性下肢深静脉瓣膜功能不全39条患肢,行SEPS＋大隐静脉高位结扎术＋腔内激光（endovenous laser treatment EVLT）＋股浅静脉瓣膜包窄术;B组：轻度原发性深静脉瓣膜功能不全24条患肢,行SEPS＋大隐静脉高位结扎＋EVLT;C组：高位结扎＋抽剥术溃疡复发者19条患肢,行SEPS＋EVLT。结果术后患肢症状和浅静脉曲张消失。76例患肢溃疡在术后14-60天内全部愈合。结论SEPS联合手术具有微创、安全、并发症少的特点,治疗下肢静脉性溃疡疗效满意。     

激光联合大隐静脉高位结扎及点式剥脱术治疗大隐静脉曲张54例治疗体会

目的探讨激光联合大隐静脉高位结扎和点动脉内膜切除术治疗大隐静脉曲张的临床疗效。方法对54例（68条肢体）大隐静脉曲张的病人实施激光联合大隐静脉高位结扎及点式剥脱术治疗。结果所有患者术后均恢复良好,无下肢深静脉血栓形成。随访3～8个月,无复发。结论激光联合大隐静脉高位结扎及点式剥脱术治疗原发性大隐静脉曲张,具有安全,有效、微创等优点。     

大隐静脉高位结扎联合腔内激光闭合术治疗下肢静脉曲张的临床效果

目的:探讨大隐静脉高位结扎联合腔内激光闭合术治疗下肢静脉曲张的临床效果。方法:选取某院收治的120例下肢静脉曲张病人为研究样本,以便利抽样法分为对照组与联合组各60例,对照组采取常规大隐静脉高位结扎剥脱术治疗,联合组在此基础上结合腔内激光闭合术治疗,对两组病人临床疗效进行观察对比。结果:两组手术时间、溃疡愈合率、色素沉着减退率、复发率比较无明显差异,P0.05;联合组术中出血量、切口长度、并发症发生率明显少于对照组,P0.05。结论:大隐静脉高位结扎联合腔内激光闭合术与常规大隐静脉高位结扎剥脱术均是治疗下肢静脉曲张的有效术式,但联合手术对病人造成的创伤和术后并发症更少,有临床应用价值。     

EVLT联合静脉高位结扎治疗下肢静脉曲张围手术期护理

大隐静脉曲张是血管外科常见病，与先天性全身结缔组织薄弱有关传统的手术方法是大隐静脉高位结扎加分段剥脱术，具有创伤大、手术时间长、瘢痕多、欠美观术后易复发等不足。EVLT联合静脉高位结扎治疗大隐静脉曲张是我科开展的一项新技术，此手术操作简便易行，创伤轻，安全性好，痛苦小，并发症少，术后恢复快且具有美容效果。其护理与传统手术有许多不同之处，现将我科于2006年10月至2007年11月采用EVLT联合静脉高位结扎治疗下肢静脉曲张患者113例患者护理体会报告如下。     

高位结扎联合静脉腔内激光治疗大隐静脉曲张72例分析

<正>大隐静脉曲张是外科常见疾病,传统的高位结扎、分段剥脱手术存在创伤大、切口多、遗留瘢痕影响美观等缺点,而静脉腔内激光术(endovenous laser treatment,EVLT)治疗下肢静脉曲张因其创伤小、恢复快,在国内外迅速开展[1]。笔者所在医院普外科于2016年11月—2017年12月共采用高位结扎联合静脉腔内激光治疗大隐静脉曲张72例(96     

同期邮票植皮术治疗大隐静脉曲张伴下肢溃疡的临床研究

目的 比较同期邮票植皮术与传统方法治疗大隐静脉曲张伴下肢溃疡的临床效果.方法 回顾性收集我院外科2016年6月～2020年5月收治的89例大隐静脉曲张合并下肢溃疡患者临床资料,根据手术时间和手术方式的不同分为对照组和治疗组,其中43例采用传统方法(大隐静脉高位结扎+激光腔内治疗+曲张静脉剥脱术+静脉皮下环缝术)的设为对...     

Novel non-operative treatment and treatment strategies in pancreatic cancer

Patients with advanced pancreatic cancer have traditionally been treated with palliative care only. The last decade has seen significant improvements in the surgical treatment of this disease but until the late 1990s there was no effective non-surgical treatment for these tumours. The introduction of gemcitabine has given clinicians treating patients with pancreatic cancer a new option. The published randomised data of gemcitabine in patients with pancreatic cancer has shown both a small survival advantage and significant improvements in quality of life indicators in these patients. These data have stimulated a resurgence of interest in pancreatic tumours and several studies have been or are currently investigating novel treatments or treatment strategies. The explosion in the molecular knowledge of cancer has led to the development of several ‘molecular designer drugs’ that have been tested in pancreatic cancer. The furthest advanced of these is a matrix metalloproteinase (MMP) inhibitor called marimastat. The first randomised data using this new class of agents is increasing and suggests that marimastat may have a role in the future treatment of patients with pancreatic cancer. Other agents such as gastrimmune, are about to enter Phase III studies and several other molecular treatment strategies are progressing from the in vitro stage towards the clinical arena. Each of these treatments and treatment regimens are discussed along with their current progress.     

十二指肠憩室手术治疗12例

目的：探讨十二指肠憩室的手术治疗。方法：对本院1998年1月～2010年6月收治的12例十二指肠憩室手术治疗患者的临床资料进行回顾性分析。结果：十二指肠憩室手术治疗12例中,憩室切除术4例,憩室内翻缝合3例,十二指肠转流手术5例（远端胃切除BillrothⅡ式2例,胃空肠Roux-en-Y吻合术3例）。术后随访1年,除1例远端胃切除BillrothⅡ式术后患者右上腹疼痛无明显缓解外,其他的均获得较为满意的效果。结论：憩室切除、憩室内翻缝合和十二指肠转流术均可以有效治疗十二指肠憩室,应根据憩室部位合理选择手术方式。     

Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran

The goal of this study was to evaluate the efficacy of 1-, 3-, and 8-mg per day doses of buprenorphine in the maintenance treatment of opium-dependent patients over a 6-month treatment period. Participants were 513 opium-dependent individuals who were seeking treatment in an urban outpatient clinic, offering a 1-hr weekly individual counseling session. Overall, 305 patients (59.5%) completed the 6-month study. Completion rates by dosage group were 33.9% for the 1-mg dose group, 64.3% for the 3-mg dose group, and 80.1% for the 8-mg dose group—each significantly different from the other two groups. The results support the efficacy and safety of buprenorphine for outpatient treatment of opium dependence and seem to indicate that the highest dose (8 mg) of buprenorphine was the best of the three doses for Iranian opium-dependent patients to increase their retention in treatment.     

Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness

In New Zealand approximately 4600 people receive opioid substitution treatment (OST) for opioid dependence, primarily methadone maintenance treatment. This study explored ways in which OST could be improved, given the significant waiting times for treatment. Two parallel surveys were conducted: 1) peer interviews with 85 regular daily or almost daily opioid drug users (51.8% receiving OST, 18.8% not currently receiving OST, and 29.4% never received OST) and; 2) a census of all 18 specialist OST service providers. When asked how OST might be improved, the four categories most commonly cited by the opioid users were 'better treatment by staff', 'more flexibility', 'better takeaway arrangements', and 'decreased waiting time'. Both opioid users and specialist services rated 'restricted takeaways' and 'having to go on a waiting list' in the top three perceived barriers to OST. Almost all services reported significant resource issues and barriers to the transfer of stable clients from specialist services to continuing treatment in primary care. The findings from this study indicate how OST can be made more accessible and attractive and thus achieve better uptake and retention.